Persistence and adherence with antihypertensive drug therapy in a German sickness fund population

Journal of Human Hypertension

Volumn 21, Issue 9, 2007, Pages 744-746

  Hoer A ^a   Gothe, H ^a   Khan, Z M ^b   Schiffhorst, G ^a   Vincze, G ^b   Haussler B ^a  

^a IGES Institute for Healthcare and Social Research Ltd   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; FEMALE; FUNDING; GERMANY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; GERMANY; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 34548315762     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002223     Document Type: Article

References (12)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
2. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-745.
3. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
4. World Health Organization. Adherence to Long-term Therapies. Evidence for Action. World Health Organization: Geneva, 2003.
5. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records: Description and validation. Med Care 1988; 26: 814-823.
6. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzi SJ. Four year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2006; 23: 1999-2010.
7. Degli Esposti E, Sturani A, Di Martino M, Falasca P, Novi MV, Baio G et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 439-444.
8. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans' Affairs healthcare system.Ann Pharmacother 2002; 36: 986-991.
9. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-575.
10. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003; 9: 424-429.
11. Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: A PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14: 795-803.
12. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/.